BioSpace News Archive

Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, today announced the enrollment of the first patient in the Phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure

Arrowhead Pharmaceuticals, Inc. (RE )--NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.

ATMPS Ltd, a leader in blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, today announce a global collaboration to create seamless integration between their respective data platforms to support the development of Advanced Therapies.

Presentations include data highlighting real-world use of RECELL in combination with complementary treatments, clinical versatility, and cost effectiveness of RECELL to advance patient care

The clinic opened in March and offers a comfortable and convenient location for ScreenPro clients.

To help accelerate innovation in Canada’s biotechnology industry, BIOTECanada and Cognit.ca are partnering to launch the Biotechnology R&D Portal and the Biotechnology R&D Showcase webinar series.

MustGrow’s safe and effective natural, organic biofumigant, biopesticide and bioherbicide are plant-based

Tryp would like to invite all current shareholders and prospective investors to connect directly with Tryp’s management team to discuss many of the Company’s achievements since its Initial Public Offering in December 2020 and look ahead to additional developments in 2021.

A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally.

HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office.